LATE-BREAKING POSTERS

- (Abstract #136-LB) Treatment Maintenance Duration of Dual Therapy with Metformin and Sitagliptin in Type 2 Diabetes - The ODYSSÉE Observational Study. P. Valensi. Sunday, June 15, 12:00 to 2 p.m. PT. Location: Poster Hall (Hall D-North).


- (Abstract #169-LB) Assessing Time to Insulin Use among Type 2 Diabetes Patients Treated with Sitagliptin or Sulfonylurea plus Metformin Dual Therapy. L. Blonde. Sunday, June 15, 12-2 p.m. PT. Location: Poster Hall (Hall D-North).

POSTERS ON CLINICAL RESEARCH

Clinical Therapeutics/New Technology – Oral Agents

- (Abstract #1027-P) Patterns of Reported Nocturnal Hypoglycemia in Patients with Type 2 Diabetes Intensively Treated with Insulin Glargine with or without Sitagliptin. R. Shankar.  
  o Guided Audio Poster Tour, Saturday, June 14, 12:30-1:30 p.m. PT. Location: Poster Hall (Hall D-North).  
  o General Poster Session, Sunday, June 15, 12-2 p.m. PT. Location: Poster Hall (Hall D-North).

- (Abstract #1039-P) Addition of Sitagliptin Improved Glycemic Control and Was Well Tolerated in Japanese Patients with Type 2 Diabetes on Glinides Monotherapy. N. Tajima. Sunday, June 15, 12-2 p.m. PT. Location: Poster Hall (Hall D-North).

- (Abstract #1080-P) Absorption, Metabolism and Excretion of Omarigliptin, a Once-Weekly DPP-4 Inhibitor, in Humans. S. Xu. Sunday, June 15, 12-2 p.m. PT. Location: Poster Hall (Hall D-North).

POSTERS ON OBSERVATIONAL STUDIES

Epidemiology

- (Abstract #1426-P) Sulfonylurea Use and Risk of Coronary Heart Disease among Patients with Type 2 Diabetes: Prospective Cohort Study among Women. Y. Li.  
  o Guided Audio Poster Tour, Saturday, June 14, 11:30 a.m.-12:20 p.m. PT. Location: Poster Hall (Hall D-North).
General Poster Session, Sunday, June 15, 12-2 p.m. PT. Location: Poster Hall (Hall D-North).

- (Abstract #1521-P) Factors Associated with Discontinuation of Sulfonylurea Therapy in Type 2 Diabetes Patients Who Initiate Insulin. Y. Qiu. Sunday, June 15, 12-2 p.m. PT. Location: Poster Hall (Hall D-North).

- (Abstract #1522-P) Risk Factors Associated with Treatment Discontinuation and Down-Titration in Type 2 Diabetes Patients Treated with Sulfonylureas. Y. Qiu. Sunday, June 15, 12-2 p.m. PT. Location: Poster Hall (Hall D-North).

- (Abstract #1528-P) Prevalence of Missed Doses of Oral Agents for Diabetes among U.S. Patients with Type 2 Diabetes. S. Rajpathak. Sunday, June 15, 12-2 p.m. PT. Location: Poster Hall (Hall D-North).

- (Abstract #1431-P) Characterization of Sitagliptin Use in Patients with Type 2 Diabetes and Chronic Renal Disease. K. Brodovicz. Sunday, June 15, 12-2 p.m. PT. Location: Poster Hall (Hall D-North).

Therapeutics/New Technology – Oral Agents

- (Abstract #1061-P) Urinary Albumin Secretion in Type 2 Diabetes Patients with Albuminuria Treated with Sitagliptin as Add-on Therapy to Metformin: a Real-World Data Study. A. Karasik. Sunday, June 15, 12-2 p.m. PT. Location: Poster Hall (Hall D-North).

- (Abstract #1168-P) Adherence to Treatment Guidelines in Type 2 Diabetes Patients Treated with Metformin Monotherapy with Suboptimal Glycemic Control in Israeli Managed Care. K. Tunceli. Sunday, June 15, 12-2 p.m. PT. Location: Poster Hall (Hall D-North).